Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gliomas
Biotech
Nuvation cancels plans to directly challenge Servier's Voranigo
Nuvation’s plans for its brain-penetrant mIDH1 inhibitor, called safusidenib, had involved a head-to-head study against Voranigo.
James Waldron
Nov 4, 2025 7:10am
NCI axes funding for pediatric brain cancer trial consortium
Aug 26, 2025 6:50am
Day One jets off with Sprint's VRK1 program for up to $316M
Aug 16, 2023 10:47am
ASCO: Servier finds survival benefit in difficult brain cancer
Jun 5, 2023 8:55am
DeepGlioma AI classifies brain tumors within 90 seconds: study
Mar 27, 2023 8:15am
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
Mar 14, 2023 10:15am
